Insider Trading Alert - Global Payments And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 10, 2013, 38 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $577.20 to $11,029,512.00.

Highlighted Stocks Traded by Insiders:

Global Payments (GPN) - FREE Research Report

Tornay Suellyn P who is Executive Vice President at Global Payments sold 10,000 shares at $55.10 on Oct. 10, 2013. Following this transaction, the Executive Vice President owned 27,853 shares meaning that the stake was reduced by 26.42% with the 10,000 share transaction.

The shares most recently traded at $54.83, down $0.27, or 0.49% since the insider transaction. Historical insider transactions for Global Payments go as follows:

  • 4-Week # shares sold: 12,608
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 12,608
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 12,608

The average volume for Global Payments has been 663,000 shares per day over the past 30 days. Global Payments has a market cap of $3.7 billion and is part of the services sector and diversified services industry. Shares are up 9.49% year to date as of the close of trading on Friday.

Global Payments Inc. The stock currently has a dividend yield of 0.16%. The company has a P/E ratio of 18.0. Currently there are 10 analysts that rate Global Payments a buy, 2 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GPN - FREE

TheStreet Quant Ratings rates Global Payments as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Global Payments Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

DSW (DSW) - FREE Research Report

Sonnenberg Harvey L who is Director at DSW sold 1,000 shares at $84.55 on Oct. 10, 2013. Following this transaction, the Director owned 6,612 shares meaning that the stake was reduced by 13.14% with the 1,000 share transaction.

The shares most recently traded at $85.49, up $0.94, or 1.1% since the insider transaction. Historical insider transactions for DSW go as follows:

  • 4-Week # shares sold: 1,497
  • 12-Week # shares sold: 1,497
  • 24-Week # shares sold: 2,994

The average volume for DSW has been 346,900 shares per day over the past 30 days. DSW has a market cap of $3.1 billion and is part of the services sector and retail industry. Shares are up 29.3% year to date as of the close of trading on Friday.

DSW Inc. operates as a branded footwear and accessories specialty retailer in the United States. The company offers fashion, shoes, dress, casual and athletic footwear, and accessories for women and men through its DSW stores and dsw.com. The stock currently has a dividend yield of 1.18%. The company has a P/E ratio of 26.7. Currently there are 2 analysts that rate DSW a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DSW - FREE

TheStreet Quant Ratings rates DSW as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full DSW Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Macquarie Infrastructure Company (MIC) - FREE Research Report

Macquarie Infrastructure Management (USA) INC who is Director at Macquarie Infrastructure Company sold 206,700 shares at $53.36 on Oct. 10, 2013. Following this transaction, the Director owned 2.8 million shares meaning that the stake was reduced by 6.97% with the 206,700 share transaction.

The shares most recently traded at $53.92, up $0.56, or 1.04% since the insider transaction.

The average volume for Macquarie Infrastructure Company has been 265,000 shares per day over the past 30 days. Macquarie Infrastructure Company has a market cap of $2.8 billion and is part of the services sector and wholesale industry. Shares are up 16.4% year to date as of the close of trading on Friday.

Macquarie Infrastructure Company LLC, through its subsidiaries, owns, operates, and invests in a diversified group of infrastructure businesses in the United States. The stock currently has a dividend yield of 6.6%. Currently there are 5 analysts that rate Macquarie Infrastructure Company a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MIC - FREE

TheStreet Quant Ratings rates Macquarie Infrastructure Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Macquarie Infrastructure Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Cozadd Bruce C who is Chairman and CEO at Jazz Pharmaceuticals sold 4,000 shares at $88.58 on Oct. 10, 2013. Following this transaction, the Chairman and CEO owned 625,647 shares meaning that the stake was reduced by 0.64% with the 4,000 share transaction.

The shares most recently traded at $88.97, up $0.39, or 0.44% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 29,208
  • 24-Week # shares sold: 49,208

The average volume for Jazz Pharmaceuticals has been 669,600 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $5.1 billion and is part of the health care sector and drugs industry. Shares are up 65.15% year to date as of the close of trading on Friday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 18.7. Currently there are 11 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

SanDisk (SNDK) - FREE Research Report

Lego Catherine P who is Director at SanDisk sold 6,000 shares at $60.94 on Oct. 10, 2013. Following this transaction, the Director owned 282,254 shares meaning that the stake was reduced by 2.08% with the 6,000 share transaction.

The shares most recently traded at $62.28, up $1.34, or 2.15% since the insider transaction. Historical insider transactions for SanDisk go as follows:

  • 4-Week # shares sold: 16,611
  • 12-Week # shares sold: 16,611
  • 24-Week # shares sold: 18,692

The average volume for SanDisk has been 4.8 million shares per day over the past 30 days. SanDisk has a market cap of $14.4 billion and is part of the technology sector and computer hardware industry. Shares are up 38.16% year to date as of the close of trading on Friday.

Sandisk Corporation designs, develops, manufactures, and markets flash storage card products that are used in various consumer electronics products. The stock currently has a dividend yield of 1.5%. The company has a P/E ratio of 20.6. Currently there are 15 analysts that rate SanDisk a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNDK - FREE

TheStreet Quant Ratings rates SanDisk as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full SanDisk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing